Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Treating Traumatic Brain Injury

This article was originally published in Start Up

Executive Summary

Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?

You may also be interested in...



Axerion Therapeutics Inc.

Axerion Therapeutics Inc.'s technology aims to block the binding of Amyloid beta to the prion protein PrP-C, a mechanism its scientists say is the toxic trigger behind neuronal death in Alzheimer's disease. Based at Yale University in New Haven, the team found that mice with AB plaques but no PrP-C showed no cognitive impairment. (Also see "Axerion Therapeutics Inc." - Scrip, 1 Jul, 2010.)

Axerion Therapeutics Inc.

Axerion Therapeutics Inc.'s technology aims to block the binding of Amyloid beta to the prion protein PrP-C, a mechanism its scientists say is the toxic trigger behind neuronal death in Alzheimer's disease. Based at Yale University in New Haven, the team found that mice with AB plaques but no PrP-C showed no cognitive impairment. (Also see "Axerion Therapeutics Inc." - Scrip, 1 Jul, 2010.)

Braintact Ltd.

Following a serious blow to the head, the initial damage to the brain may seem limited, but it's what happens afterwards that determines a victim's fate. Tragically, a few hours or even days later, the trauma may prove to have caused permanent or fatal damage. The amino acid neurotransmitter glutamate (Glu) plays a major role in the delayed but catastrophic reaction. Various pharmaceutical approaches to halting Glu-precipitated damage have thus far failed. Braintact proposes an entirely new way to treat TBI, stroke and even chronic brain diseases such as brain tumors. It seeks to lower the Glu levels in plasma without, however, touching the Glu release or receptor processes in the brain.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel